No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a personalized gene-corrected cell therapy that has progressed to Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. The company's pipeline also encompasses several other programs: ABO-102, an adeno-associated virus (AAV)-based gene therapy designed for Sanfilippo syndrome type A; ABO-201, aimed at CLN3 disease; ABO-401, targeting cystic fibrosis; and ABO-50X, intended for genetic eye disorders. Additionally, Abeona actively advances AAV-based gene therapies through its proprietary AIM vector platform. Incorporated in 1974, the firm was initially named PlasmaTech Biopharmaceuticals, Inc. before officially adopting the name Abeona Therapeutics Inc. in June 2015. The company's corporate base is situated in New York, New York.
www.abeonatherapeutics.comNo one on the platform currently holds 0H7R.L.
No tracked institution reports a position in 0H7R.L as of their last filing.
No one on the platform has traded 0H7R.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -84.5% | — | — | — | ||
| Rev. Growth % | -10.3% | |||||
| Profit Margin % | 1223.1% | |||||
| Free Cash Flow Margin % | -1448.5% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $54M | +1026.3% | $-0.95 | $-1.59–$-0.59 | — | 1 |
| 2027 | $119M | +118.7% | $-0.19 | $-0.31–$-0.12 | — | 1 |
| 2028 | $180M | +51.2% | $0.38 | $0.23–$0.63 | — | 1 |
| 2029 | $281M | +56.6% | $1.45 | $0.89–$2.43 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.23 | $-0.35 | -51.1% |
| 2026-05-13 | $-0.34 | $-0.30 | +10.4% |
| 2026-03-17 | $-0.35 | $-0.36 | -2.3% |
| 2025-11-12 | $-0.28 | $-0.10 | +66.3% |
| 2025-08-14 | $-0.39 | $1.63 | +517.9% |
| 2025-05-15 | $-0.36 | $-0.24 | +33.0% |
| 2025-03-20 | $-0.35 | $-0.50 | -43.7% |
| 2024-11-14 | $-0.39 |
| $-0.63 |
| -60.5% |
| -3.62% |
| $119M |
| — |
| 0IFK.LEditas Medicine, Inc. | $2.91 | +7.31% | $269M | — |
| 0IL8.LKyntra Bio, Inc. | $7.75 | +1.77% | $31M | — |
Source: Financial Modeling Prep · peers by sector/industry